Claybrook Capital, LLC Vertex Pharmaceuticals Inc Transaction History
Claybrook Capital, LLC
- $172 Million
- Q3 2023
Shares
4 transactions
Others Institutions Holding VRTX
# of Institutions
1,721Shares Held
227MCall Options Held
1.21MPut Options Held
1.56M-
Capital World Investors Los Angeles, CA26.8MShares$13.3 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$11.5 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.5 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.7MShares$5.8 Billion0.24% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$4.45 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $127B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...